Pramlintide vs Tesofensine
A side-by-side research comparison of Pramlintide and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Pramlintide | Tesofensine |
|---|---|---|
| Full name | Pramlintide (Symlin) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | FDA Approved | Phase 3 Clinical Trial |
| Mechanism | Mimics amylin by activating amylin receptors, which slows gastric emptying, suppresses inappropriate glucagon secretion after meals, and increases satiety - complementing insulin's effects. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | 3949.4 Da | 329.4 Da |
| Half-life | ~48 minutes | 8-10 days |
| Bioavailability | Subcutaneous injection | High (oral ~93%) |
| Typical dose | 15-120 mcg before meals | 0.25-0.5 mg |
| Frequency | Before major meals | Once daily |
| Route | Subcutaneous injection | Oral |
Pramlintide reported benefits
- Appetite suppression and satiety
- Slows gastric emptying
- Improves post-meal glucose control
- Modest weight loss
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.